PharmAla Biotech is the only company currently sourcing finished, clinical grade LaNeo™ MDMA Drug Product in North America. PharmAla’s drug API is encapsulated under GMP conditions, and is available to entities who have Controlled Substances licenses, Section 56 Ministerial Exemptions, or Clinical Trial numbers within Canada. Drug Product can also be exported for use by clinical trial practitioners globally, subject to the issuance of import and export permit.